Ryan Merkow, MD, MS, and Louise Catherine Connell, MB BCh BAO, BMedSc, discuss the current treatment landscape in colorectal cancer liver metastases, highlighting unmet needs in the treatment space.
Agenus Inc. (AGEN) stock is falling over 14 percent on Friday morning after the announcement of updated data from its phase 1 clinical trial of BOT/BAL combination therapy in patients with metastatic colorectal cancer, that is not microsatellite instability-high or MSS, or deficient mismatch repair or dMMR.